BackCrinetics Pharmaceuticals Overview
Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Target Price

Analysts' average 12-month price target for Crinetics Pharmaceuticals is $82.

Get informed when a big investor buys or sells

+ Follow

Share Price

$84.95

Average Target Price

$81.703.8% downside

10 analysts in the last 4 months

High: $88 | Low: $55

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-28UBS$850.1% upsideOpen
2026-07-08Stifel NicolausAlex Thompson$850.1% upsideOpen
2026-07-08Evercore ISI$850.1% upsideOpen
2026-07-07Jefferies$850.1% upsideOpen
2026-07-07H.C. Wainwright$850.1% upsideOpen
2026-07-07Robert W. Baird$850.1% upsideOpen
2026-07-02UBSAshwani Verma$5535.3% downsideOpen
2026-06-22Stifel NicolausAlex Thompson$832.3% downsideOpen
2026-06-15H.C. WainwrightDouglas Tsao$814.6% downsideOpen
2026-05-15Evercore ISIGavin Clark-Gartner$883.6% upsideOpen
2026-05-11Oppenheimer$841.1% downsideOpen
2026-01-30Stifel Nicolaus$841.1% downsideOpen
2026-01-12Goldman SachsRichard Law$6721.1% downsideOpen
2026-01-08Morgan Stanley$872.4% upsideOpen
2026-01-08China Renaissance Securities (US) Inc.$10523.6% upsideOpen
2026-01-05Evercore ISI$905.9% upsideOpen
2026-01-05Stifel NicolausAlex Thompson$7511.7% downsideOpen
2025-09-30Oppenheimer$872.4% upsideOpen
2025-09-28Morgan Stanley$779.4% downsideOpen
2025-09-26JMP SecuritiesJonathan Wolleben$14368.3% upsideOpen
2025-07-10Goldman SachsRichard Law$3657.6% downsideOpen
2025-03-24Stifel NicolausAlex Thompson$6029.4% downsideOpen
2025-02-28JMP Securities$917.1% upsideOpen
2024-08-09H.C. WainwrightDouglas Tsao$6918.8% downsideOpen
2024-06-04OppenheimerLeland Gershell$7412.9% downsideOpen
2024-05-23Robert W. BairdBrian Skorney$6227% downsideOpen
2024-05-22Morgan StanleyJeffrey Hung$7017.6% downsideOpen
2024-05-07Piper SandlerYasmeen Rahimi$9714.2% upsideOpen
2024-03-20JMP SecuritiesJonathan Wolleben$805.8% downsideOpen
2024-03-13OppenheimerLeland Gershell$5436.4% downsideOpen
2023-08-31OppenheimerLeland Gershell$4052.9% downsideOpen
2022-05-26Leerink Partners$3954.1% downsideOpen

Crinetics Pharmaceuticals (CRNX) FAQ

Crinetics Pharmaceuticals's target price stands at $82. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $82 for CRNX implies 3.8% downside versus today's price ($84.95). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Crinetics Pharmaceuticals's target price evolved across reporting periods, while the comparison chart places CRNX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Crinetics Pharmaceuticals's reading of $82 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.